



### **Enttheon Announces Resignation of Ruth Chun**

Vancouver, British Columbia— (March 1, 2023) - Enttheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("**Enttheon**" or the "**Company**") announces that Ruth Chun has resigned as a director of the Company effective February 28, 2023. The Company benefitted from Ms. Chun's expertise in corporate and legal matters and would like to thank her for her contributions and services as a director of Enttheon.

"I want to thank Ms. Chun for all of her hard work over the past two years. Management and the Board of Directors appreciated her dedication to the company and wish her well on her future endeavours."

Timothy Ko – CEO and Director

#### **About Enttheon Biomedical Corp.**

Enttheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

#### **For more information, please contact the Company at:**

Enttheon Biomedical Corp.

Timothy Ko, CEO

[timothy@enttheonbiomedical.com](mailto:timothy@enttheonbiomedical.com)

<https://enttheonbiomedical.com/>.

*The Canadian Securities Exchange has not approved nor disapproved the contents of this news release.*